CompaniesBerGenBio
BerGenBio logo

BerGenBio

active
Bergen, Norway
Founded 2008
Website
About

Target Identification & Small Molecules

Areas of Focus

Categories

Non-PharmaceuticalSmall Molecule PharmaceuticalNorway
Team (11)
Cristina Oliva
Cristina Oliva
Cristina Oliva
BerGenBio
team_member
Dr. Debra Barker
Dr. Debra Barker
Dr. Debra Barker
BerGenBio
team_member
Dr. Sally Bennett
Dr. Sally Bennett
Dr. Sally Bennett
BerGenBio
team_member
Enriqueta FelipM.D., Ph.D.
Enriqueta FelipM.D., Ph.D.
Enriqueta FelipM.D., Ph.D.
BerGenBio
team_member
John HeymachM.D., Ph.D.
John HeymachM.D., Ph.D.
John HeymachM.D., Ph.D.
BerGenBio
team_member
Mr. Anders Tullgren
Mr. Anders Tullgren
Mr. Anders Tullgren
BerGenBio
team_member
View all 11 team members →
Clinical Trials (15)
View all

Total Trials

15

As Lead Sponsor

9

As Collaborator

6

Total Enrollment

824

By Phase

PHASE1/PHASE2: 5PHASE1: 3PHASE2: 5EARLY_PHASE1: 2

By Status

COMPLETED: 9TERMINATED: 5UNKNOWN: 1
Clinical Trials Pipeline15 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
NCT02488408
NCT02424617
NCT02922777
NCT02872259
NCT03184571
NCT03824080
NCT03649321
NCT03654833
NCT03965494
Hover over trial bars to see details

Recent Trials

NCT05469178Lead Sponsor
A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene
PHASE1/PHASE2Terminated
26 participants
Started: Mar 6, 2023 · Completed: Apr 3, 2025
NCT06469138Lead Sponsor
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
PHASE1Completed
6 participants
Started: Aug 2, 2022 · Completed: Sep 23, 2022
NCT04893551Lead Sponsor
A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants
PHASE1Terminated
16 participants
Started: Feb 25, 2021 · Completed: Jun 27, 2022
NCT04890509Lead Sponsor
A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
PHASE2Completed
115 participants
Started: Oct 20, 2020 · Completed: May 25, 2021
NCT03965494Collaborator
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
EARLY_PHASE1Terminated
10 participants
Started: Jan 2, 2020 · Completed: Oct 31, 2023
View all 15 trials →
Locations (1)
Headquarters
Bergen, Norway
Map

Loading map...